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Abstract Constitutively active tyrosine kinases are frequently
expressed in various types of human leukemias as the result of
chromosomal translocations. The TEL^Jak2 fusion oncoprotein
possesses transforming properties in both animal and cellular
models, that are tightly dependent on Stat5 activation. In the IL-
3-independent TEL^Jak2-transformed Ba/F3 cells, activation of
the PI-3K/Akt pathway appears essential to cell proliferation.
Here we report a sustained activation of NF-UB factors in Ba/F3
cells, which inhibition dramatically impairs cell viability,
indicating that NF-UB signaling exerts a major role in the anti-
apoptotic activities of TEL^Jak2 oncoprotein. ß 2001 Feder-
ation of European Biochemical Societies. Published by Elsevier
Science B.V. All rights reserved.
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1. Introduction
NF-UB transcription factors act as important mediators in
acute and inducible cellular responses to a variety of extracel-
lular stimuli, in particular in the immune system (reviewed in
[1]). Mammalian NF-UB includes the RelA/p65, RelB, c-Rel,
p50/p105 and p52/p100 proteins, structurally related through
a Rel homology (RH) domain implicated in their DNA bind-
ing, dimerization and interaction with IUB inhibitor proteins.
NF-UB transcriptional activity is primarily controlled by cy-
toplasm retention of the complexes by any of several IUB
family members (reviewed in [2]). The extracellular signals
leading to the activation of NF-UB focus on the IKK complex
responsible for the phosphorylation of IUB. These phosphor-
ylations lead to IUB proteasome-mediated degradation and
allow in turn translocation of NF-UB complexes into the nu-
cleus where they can modulate speci¢c gene expression.
As the NF-UB signaling pathway participates in the control
of apoptosis and cell proliferation, it is a target for transform-
ing activities of viral and cellular oncogenes. Disregulated
NF-UB activity has been reported in human hematopoietic
and solid tumors, due to direct alterations of genes encoding
components of the NF-UB pathway or by yet uncharacterized
mechanisms (reviewed in [3]). Constitutively activated tyrosine
kinase oncoproteins, BCR-ABL [4] and TEL-PDGFLR [5]
have been shown to activate the NF-UB pathway. The
TEL^Jak2 fusion protein, observed in various human hema-
topoietic malignancies [6,7] represented the ¢rst example of
the direct involvement of the Jak-Stat pathway in human
oncogenesis. In this report, NF-UB activity was evaluated in
murine lymphoid Ba/F3 cells transformed by TEL^Jak2 and
compared with that of TEL^ABL expressing cells [8].
2. Materials and methods
2.1. Cell culture and reagents
The parental Ba/F3 cells were grown in RPMI 1640 medium with
10% fetal calf serum and 4% WEHI conditioned medium (WCM) as a
source of IL-3. Stimulation experiments were performed with re-
combinant murine IL-3 (Valbiotech). The IL-3-independent Ba/F3
cells stably expressing the TEL^Jak2 and TEL^ABL fusions have
been described [9]. The Ba/F3v31 cell line expresses a dominant neg-
ative form of the Stat5A protein [10].
2.2. Nuclear extracts and electrophoretic mobility shift assay (EMSA)
Deprivation was for 16 h in the absence of WCM for parental Ba/
F3 cells. Nuclear extracts were performed as described [11]. For EM-
SAs, 10 Wg of nuclear extracts (determined with the BCA protein
assay reagent (Pierce)) were incubated in a bu¡er containing 20 mM
HEPES, 4% Ficoll, 70 mM NaCl, 2 mM dithiothreitol, 100 Wg/ml
bovine serum albumin and 0.01% NP40 with 32P-labeled NF-UB
probe (AGTTGAGGGGACTTTCCCAGG). Rabbit polyclonal anti-
bodies raised against the p50 and p65 were kindly provided by Nancy
Rice (NCI-FCRDC, Frederick, MD, USA). For experiments using
the speci¢c inhibitor of IUBK phosphorylation BAY 11-7082 (Calbio-
chem), cells were incubated 1 h in the presence of 5 or 10 WM of the
compound prior to nuclear protein extraction.
2.3. Transient transfection reporter assays
For NF-UB luciferase reporter assay, 0.35U106 cells/ml of the dif-
ferent cell lines were transfected with the indicated amounts of lucif-
erase reporter pNF-UB-Luc plasmid (PathDetect NF-UB cis-reporting
system, Stratagene) using the Lipofectin reagent (Gibco BRL). Cells
were collected 48 h post transfection and lysed in the reporter lysis
bu¡er (Promega). Luciferase assays were performed with 15^20 Wg of
lysates using the kit Luciferase assay system (Promega) in a Lumat
LB9501 (Berthold). Luciferase activities are expressed as fold induc-
tion relative to values obtained from normally growing parental Ba/
F3 cells cultured in WCM.
2.4. Apoptosis study
Parental Ba/F3 and Ba/F3v31 cells were incubated for 16 h in the
absence of WCM then cultured one h with or without 10 WM of BAY
11-7082, 10 WM of the MEKK kinase inhibitor UO126 (Calbiochem)
or 20 WM of the p38 inhibitor SB 203580 (Calbiochem) and then
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stimulated with 10 ng/ml of recombinant IL-3 for the indicated times.
The TEL^Jak2- and TEL^ABL-expressing Ba/F3 cells were cultured
with or without identical concentrations of the inhibitors. Cells were
washed once in the incubation bu¡er (10 mM HEPES^NaOH, pH
7.4; 140 mM NaCl; 5 mM CaCl2) and resuspended in the incubation
bu¡er with 0.5 Wg/ml of propidium iodide (Interchim) and Annexin
V-£uos (Boehringer Mannheim) at room temperature for 30 min. The
percentages of early apoptotic cells (Annexin V-£uos positive, propi-
dium iodide negative) and late apoptotic cells (Annexin V-£uos pos-
itive, propidium iodide positive) were determined by using an EPICS
Elite cytometer (Coulter Corporation, FL, USA).
2.5. Cell extracts and Western blotting
Cells were incubated 1 h in the presence of BAY 11-7082 (10 WM),
UO126 (10 WM) or SB 203580 (20 WM) and extraction (nuclear (NE)
and cytoplasmic (CE)) performed as reported [9]. For Western blot-
ting, 100 Wg of extracts were separated by electrophoresis on 10%
SDS^PAGE, transferred to cellulose membrane (Hybond-C super
membrane, Amersham Life Science) which were incubated with the
indicated antibodies. The anti-IUBK, anti-phospho(Thr180/Tyr182)-
p38 and anti-p38 antibodies were purchased from New England Bio-
labs. Immune complexes were detected using the ECL detection kit
(Amersham).
3. Results
3.1. Expression of the TEL^Jak2 and TEL^ABL fusion
proteins in Ba/F3 cells leads to the activation of NF-UB
complexes
We recently reported a constitutive activation of the PI-3K/
Akt pathway in TEL^Jak2- and TEL^ABL-transformed Ba/
F3 cells that appears essential for the mitogenic properties but
dispensable for the anti-apoptotic activities of these oncopro-
teins [12]. To investigate the activation of NF-UB factors in
TEL^ABL- and TEL^Jak2-expressing Ba/F3 cells, we ¢rst
examined their DNA-binding activity by EMSA (Fig. 1A).
As controls, nuclear extracts from parental cells growing in
WCM (lanes 4^6) or deprived for 16 h and left unstimulated
Fig. 1. Constitutive activation of NF-UB complexes in Ba/F3 cells transformed by the TEL^Jak2 and TEL^ABL fusions. A: Analyses of NF-
UB DNA-binding activities were performed by EMSA with nuclear extracts from the IL-3-independent TEL^Jak2 and TEL^ABL-expressing
Ba/F3 cells (lanes 7^12) and an oligonucleotide probe containing an NF-UB-binding site. As a control, nuclear extracts from parental Ba/F3
cells growing in WCM (lanes 4^6) or starved for 16 h and left unstimulated (lane 1) or stimulated with recombinant IL-3 for the indicated
times (lanes 2, 3) were loaded. Supershift experiments were performed with speci¢c anti-p50 and anti-p65 antibodies. B: To test for the inhibi-
tory impact of BAY 11-7082 on the NF-UB DNA-binding activity, the above cell lines were treated with 5 WM or 10 WM of inhibitor prior to
extraction of nuclear proteins.
Fig. 2. NF-UB complexes are transcriptionally active in the TEL^
Jak2 and TEL^ABL-expressing Ba/F3 cells. Luciferase reporter as-
says were performed on TEL^Jak2- and TEL^ABL-expressing cells
transiently transfected with the indicated amounts of a NF-UB lucif-
erase reporter plasmid. Results are expressed as fold induction rela-
tive to luciferase activities obtained in parental Ba/F3 cells growing
in WCM medium. Data shown are from representative experiments
where transfections were done in duplicate.
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(lane 1) or stimulated with recombinant IL-3 for 2 h (lane 2)
or 5 h (lane 3) were loaded. Extracts from TEL^Jak2-express-
ing cells showed roughly equivalent amounts of bound NF-UB
complexes to growing parental cell controls (compare lanes 4
and 10) indicating that TEL^Jak2 induces the activation of
NF-UB. Similarly, cells stably expressing the TEL^ABL fusion
showed a constitutive NF-UB DNA-binding activity (lane 7),
although repeatedly weaker than in the TEL^Jak2 context.
Supershift experiments using antibodies to p50 (lanes 6, 9,
12) or to p65 (lanes 5, 8, 11) indicated the presence of p50
and of p65/RelA in the complexes. C-Rel might also be
present in the complexes detected in the three cell line extracts,
as suggested by the use of anti-c-Rel antibodies (data not
shown).
Phosphorylation of the IUB inhibitors, that interact with
and sequester NF-UB subunits in the cytoplasm, leads to their
degradation and to the nuclear translocation of NF-UB fac-
tors. In order to con¢rm the activated status of NF-UB com-
plexes in our Ba/F3 cell lines, we used the BAY 11-7082
compound described as a potent inhibitor of IUBK
phosphorylation [13]. EMSA experiments using nuclear ex-
tracts from BAY 11-7082-treated cells showed a clear dose-
Fig. 3. Inhibition of the NF-UB pathway totally impairs the viability of the TEL^Jak2 and TEL^ABL-transformed Ba/F3 cells. Apoptosis anal-
ysis was performed on TEL^Jak2- and TEL^ABL-expressing cells cultured in the absence or presence of BAY 11-7082 (10 WM), as reported in
Section 2. Values are given as the percentage of total viable cells remaining in the culture. As controls, the same experiments were performed
using parental Ba/F3 cells and Ba/F3v31 cells [10] which were deprived of WWCM for 16 h, then treated or not with BAY 11-7082 (10 WM)
before being replaced in the presence of WCM for the remaining period.
Fig. 4. Activation of NF-UB signaling in TEL^Jak2- and TEL^ABL-expressing Ba/F3 cells is not mediated by the PI-3K or MAP kinase path-
ways. A: Nuclear extracts from LY294002- or UO129-treated cells were analyzed by EMSA using an oligonucleotide probe containing an NF-
UB-binding site. B: TEL^Jak2- and TEL^ABL-expressing cells were left untreated (3) or treated with LY294004 (50 WM) or UO129 (10 WM)
inhibitors or with a combination of both. The percentages of viable cells were determined as described in Section 2.
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dependent decrease in the NF-UB DNA-binding activity in
TEL^ABL (compare lanes 4^6), TEL^Jak2 (compare lanes
7^9) and IL-3 stimulated Ba/F3 cells (compare lanes 1^3)
(Fig. 1B). As shown by Western blot analyses of the same
extracts, p38 MAP kinase (see Fig. 5A) or nuclear p65 (data
not shown) proteins remained expressed at similar level in
BAY 11-7082-treated cells, ruling out a non-speci¢c e¡ect of
the inhibitor. Taken together, our results show the constitu-
tive activation of NF-UB in the two transformed Ba/F3 cell
lines.
To ensure the transcriptional activity of the activated NF-
UB complexes, we performed luciferase reporter assays. The
parental, TEL^ABL- and TEL^Jak2-expressing cells were
transiently transfected with increasing amounts of a luciferase
reporter gene containing multimers of the consensus IU-bind-
ing site. Fig. 2 shows the ratio of the measured luciferase
activities with respect to the parental Ba/F3 cells. Both
TEL^Jak2- and TEL^ABL-expressing cells demonstrated a
marked increase in NF-UB-dependent transcriptional activa-
tion, with respect to parental cell controls. This activity was
repeatedly found higher in the TEL^Jak2- than in the TEL^
ABL-expressing cells, in keeping with the di¡erences in NF-
UB DNA-binding activities observed between TEL^Jak2 and
TEL^ABL cell lines (see Fig. 1A).
3.2. Functional inhibition of NF-UB totally impairs the viability
of TEL^Jak2- and TEL^ABL-expressing Ba/F3 cells
We next examined the biological e¡ect of the BAY 11-7082
compound on the cell viability. Cell lines were cultured in the
presence or absence of BAY 11-7082 at a concentration (10
WM) that was previously shown to completely inhibit NF-UB
DNA-binding activity (cf. Fig. 1B). Cell viability was esti-
mated daily by Annexin V-propidium iodide £ow cytometry
(Fig. 3). When TEL^Jak2- and TEL^ABL-transformed Ba/F3
cells were treated, a signi¢cant decrease in cell viability was
observed after 24 h. Maximum rates of apoptotic cells were
achieved after 72 h treatment for both TEL^Jak2- and TEL^
ABL-transformed Ba/F3 cells. A lower dose of the compound
(5 WM) led to similar results although with a delayed kinetics
(data not shown). The parental Ba/F3 behaved similarly to
TEL^Jak2- and TEL^ABL-transformed cells. This was not
due to a toxic e¡ect of the drug on Ba/F3 cells since the
viability of another IL-3-dependent Ba/F3 cell line, referred
to as the Ba/F3v31 [10], was not a¡ected by this compound
even after 72 h treatment (Fig. 3).
3.3. Activation of NF-UB complexes in TEL^Jak2- and
TEL^ABL-expressing cells is independent of the PI-3K
and MAP kinase pathways
Both PI-3K and MAP kinase pathways have been reported
to functionally activate NF-UB in various hematopoietic cell
types [1]. To address the implication of these pathways in NF-
UB activation in our Ba/F3 cell lines, we examined the biolog-
ical e¡ects of the speci¢c PI-3K inhibitor LY294002 and
MEK1/2 kinase inhibitor UO126. As shown in Fig. 4A,
EMSA experiments performed with nuclear extracts did not
show obvious di¡erences in NF-UB DNA-binding activity of
cells treated with either one or both inhibitors (Fig. 4A). As
previously reported [12], treatment of TEL^Jak2- and TEL^
ABL-expressing cells with LY294002 impaired cell cycle pro-
gression but not cell viability. Similarly, the cell viability of
the two cell lines was not a¡ected upon treatment with
LY294002 or UO126 or with both inhibitors. A compilation
of these experiments is shown in Fig. 4B.
Fig. 5. Inhibition of the p38 MAP kinase does not alter the viability of TEL^Jak2- and TEL^ABL-transformed Ba/F3 cells. A: Nuclear (NE)
and cytoplasmic (CE) extracts from BAY 11-7082-treated TEL^Jak2- and TEL^ABL-expressing cells were analyzed by Western blot by using
anti-phospho p38 (upper panel) and anti-p38 (lower panel) antibodies. B: Western blot analysis of nuclear extracts from TEL^Jak2- and TEL^
ABL-expressing cells treated or not with the indicated inhibitors. C: Apoptosis analysis was performed on TEL^Jak2- and TEL^ABL-express-
ing cells cultured in the presence or not of the indicated inhibitors. Cellular viability was estimated as reported in Section 2.
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3.4. Inhibition of the p38 MAP kinase does not alter the
viability of TEL^Jak2- and TEL^ABL-expressing cells
In addition to inhibition of IUBK phosphorylation, treat-
ment with BAY 11-7082 has been reported to stimulate the
activation of the p38 MAP kinase. Accordingly, Western blot-
ting experiments showed an increase in phosphorylated p38
following BAY 11-7082 treatment of TEL^Jak2- and TEL^
ABL-Ba/F3 cells (Fig. 5A). As the MKK3/4/6 kinases known
to activate p38, are not inhibited by the UO126 compound
used in experiments shown in Fig. 4, we analyzed the e¡ect of
SB 203580, a speci¢c p38 inhibitor. EMSA analysis did not
show any variations in the NF-UB DNA-binding activity from
nuclear extracts of SB 203580-treated cells (data not shown),
as observed for other hematopoietic cell lines [14]. Levels of
phosphorylated p38 signi¢cantly decreased when cells were
incubated in 20 WM of SB 203580 prior to BAY 11-7082
treatment (Fig. 5B) without returning to a basal level (com-
pare lanes 1^4 and lanes 5^8). Annexin V-propidium iodide
£ow cytometry experiments did not reveal modi¢cation of cell
behavior in response to SB 203580 (Fig. 5C). The BAY 11-
7082-mediated apoptotic process was however more pro-
nounced in the presence of SB 203580, suggesting that a co-
operation between the NF-UB and p38 pathways might occur.
Collectively, our data support a major contribution of the
NF-UB signaling pathway in the survival mediated by the
TEL^Jak2 and TEL^ABL fusion proteins.
4. Discussion
Human hematological malignancies widely illustrate the
critical role of a disregulated NF-UB signaling in oncogenesis.
Constitutively activated NF-UB complexes are recurrently ob-
served in childhood acute lymphoblastic leukemias [15],
although the underlying molecular mechanisms are still
largely unknown. In some instances, aberrant NF-UB activity
results from the rearrangements of genes encoding the NF-UB/
IUB family members or of alterations in regulatory proteins
that control this signaling pathway. In turn, NF-UB activates
a large number of anti-apoptotic mediator genes [16] and
several cell cycle genes such as cyclin D1 that is required for
G1/S cell cycle progression [17].
In this report, we established the direct implication of this
pathway in the anti-apoptotic properties of two leukemogenic
fusion proteins TEL^Jak2 and TEL^ABL. This was not un-
expected since activation of the NF-UB pathway has also been
implicated in the transforming properties of other constitu-
tively activated tyrosine kinases associated with human hem-
atopoietic tumors [4,5]. In the BCR-ABL-expressing 32D
murine cell line, NF-UB activity is dispensable for apoptosis
inhibition upon cytokine withdrawal, but is essential for its
tumorigenicity in nude mice [4]. Similarly to BCR-ABL, TEL^
ABL is expected to activate a large number of signaling path-
ways [18^20] and several of them are likely to redundantly
focus on NF-UB activation.
Many signal transduction pathways, such as Ras/MAP ki-
nases or PI-3K/Akt, exhibit extensive cross-talk with compo-
nents of the IKK-IUB/NF-UB pathway. As shown here and in
our previous work [12], the speci¢c PI-3K inhibitor
(LY294002) and MEK inhibitor (UO126) do not alter the
survival process mediated by TEL^Jak2 in Ba/F3 cells.
Thus, the sustained activity of NF-UB is unlikely to rely on
the Ras/MAP kinase or PI-3K/Akt pathways but rather im-
plies dysregulation of components of the IKK complex or
defective IUB-mediated inhibition. In this regard, phosphory-
lations of IUBK proteins mediated by tyrosine kinases have
been reported to activate NF-UB complexes without proteo-
lytic degradation of IUBK [21].
The TEL^Jak2 oncoprotein appears to activate substrates
very similar to those activated by the normal Jak2 tyrosine
kinase. Among them, the Stat5 transcription factors are essen-
tial for its transforming activity in cellular and animals models
[9,22]. Our results suggest that Stat5 activation could be
mainly responsible for cell proliferation whereas NF-UB acti-
vation would be responsible for cell survival. Links between
the Jak2- or Stat5-mediated signaling pathways and NF-UB
activity are now to be investigated.
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